Obtenga las últimas noticias sobre las acciones de Intensity Therapeutics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de INTS

Últimas noticias sobre

INTENSITY THERAPEUTICS INC

Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

Press Releases

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

Offerings

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Opinion

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Small Cap

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Earnings

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

News

Contracts

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

ARAY

CLRB

ERAS

GRAL

IMRX

INTS

ONCY

RLAY

TSX:ONC

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

BioCardia

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Edesa Biotech

ESSA Pharma

Evogene

HCW Biologics

iBio

Imunon

Leap Therapeutics

Mustang Bio

Moleculin Biotech

Marker Therapeutics

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

OSR Holdings

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Portage Biotech

Benchmark

Brookline Capital

Alliance Global Partners

HC Wainwright & Co.

Comments

Intensity Therapeutics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL